Upadacitinib treats vitiligo

Upadacitinib (Upadacitinib) is a drug that targets inflammation and immune response and is mainly used to treat diseases such as rheumatoid arthritis and psoriatic arthritis. Although the immune system is theoretically related to the occurrence of vitiligo, the current prescribing information for upadatinib does not indicate that upadatinib can effectively treat vitiligo.

Vitiligo is a common depigmentation skin disease. Current treatment methods mainly include drug treatment, phototherapy, skin transplantation, etc. AbbVie has initiated a Phase 2b study of upapatinib in adults with non-segmental vitiligo, meeting the primary endpoint of percent change from baseline at 11 mg and 22 mg doses compared with placebo at week 24. Overall, the percentage reduction in F-VASI from baseline at Week 52 was numerically greater than the Week 24 results for all upactinib doses, and no new safety signals were identified. Based on this data, AbbVie will advance the clinical trial plan of upadatinib for the treatment of vitiligo to Phase 3.

The original drug Upatinib has been launched in China, and has subsequently entered the scope of Class B medical insurance. Only eligible patients can be reimbursed. Specifications The price of each box of 15mg*28 tablets may be around RMB 3,000. The European version of the original drug sold overseas is priced at more than 20,000 yuan for 15mg*30 tablets (the price may fluctuate due to exchange rates), which is expensive. Cheaper upadatinib generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 15mg*30 tablets produced by Bangladesh pharmaceutical factory is around 900 yuan (the price may fluctuate due to the exchange rate).